SOHM, Inc. Continues to Build its IP Portfolio in the Gene Editing and Cell Engineering Space
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has filed a new provisional patent application with the USPTO. The application, titled 'DONOR NUCLEIC ACIDS FOR RNA GUIDED INTEGRASES AND MULTIPLEX GUIDE RNA SYSTEM FOR TARGETING', describes specific combinations of guide RNAs used with the ABBIE system to increase targeting and efficiency.
This development comes ten months after SOHM's announcement of their 'SMART' gene editing provisional application. The company aims to expand its patent portfolio in the cell engineering space, with the goal of becoming a significant player and leader in gene editing technology and products.
Dr. David Aguilar, COO of SOHM, expressed satisfaction with the progress in developing the ABBIE system and its potential, stating that these technical advances provide the competitive edge needed in this highly contested field.
SOHM, Inc. (OTC PINK:SHMN), azienda farmaceutica e biotecnologica, ha presentato una nuova domanda di brevetto provvisorio presso l'USPTO. La domanda, intitolata 'ACIDI NUCLEICI DONATORI PER INTEGRASE GUIDATE DA RNA E SISTEMA MULTIPLO DI RNA GUIDA PER IL TARGETING', descrive specifiche combinazioni di RNA guida utilizzati con il sistema ABBIE per aumentare il targeting e l'efficienza.
Questo sviluppo arriva dieci mesi dopo l'annuncio da parte di SOHM della loro domanda di brevetto provvisorio per l'editing genetico 'SMART'. L'azienda mira ad espandere il proprio portafoglio di brevetti nel settore dell'ingegneria cellulare, con l'obiettivo di diventare un attore significativo e leader nella tecnologia e nei prodotti di editing genetico.
Il Dr. David Aguilar, COO di SOHM, ha espresso soddisfazione per i progressi nello sviluppo del sistema ABBIE e il suo potenziale, affermando che questi avanzamenti tecnici forniscono il vantaggio competitivo necessario in questo campo altamente contestato.
SOHM, Inc. (OTC PINK:SHMN), una empresa farmacéutica y de biotecnología, ha presentado una nueva solicitud de patente provisional ante la USPTO. La solicitud, titulada 'ÁCIDOS NUCLEICOS DONADORES PARA INTEGRAS GUIADAS POR RNA Y SISTEMA DE RNA GUIA MULTIPLEX PARA EL TARGETING', describe combinaciones específicas de RNAs guía utilizados con el sistema ABBIE para aumentar el targeting y la eficiencia.
Este desarrollo llega diez meses después del anuncio de SOHM sobre su solicitud de patente provisional para la edición genética 'SMART'. La empresa busca expandir su cartera de patentes en el ámbito de la ingeniería celular, con el objetivo de convertirse en un jugador significativo y líder en la tecnología y productos de edición genética.
El Dr. David Aguilar, COO de SOHM, expresó su satisfacción por los avances en el desarrollo del sistema ABBIE y su potencial, afirmando que estos avances técnicos proporcionan la ventaja competitiva necesaria en este campo altamente disputado.
SOHM, Inc. (OTC PINK:SHMN), 제약 및 생명공학 기업이 USPTO에 새로운 임시 특허 출원을 하였습니다. 이 출원의 제목은 'RNA 유도 인테그레이스를 위한 기증 핵산 및 타겟팅을 위한 다중 가이드 RNA 시스템'이며, ABBIE 시스템과 함께 사용되는 특정 가이드 RNA 조합을 설명합니다.
이번 개발은 SOHM이 'SMART' 유전자 편집 임시 특허를 발표한 지 10개월 만에 이루어진 것입니다. 이 회사는 세포 공학 분야에서 특허 포트폴리오를 확대할 계획이며, 유전자 편집 기술과 제품에서 중요한 플레이어이자 리더가 되는 것을 목표로 하고 있습니다.
SOHM의 COO인 Dr. David Aguilar는 ABBIE 시스템 개발의 진전 및 잠재력에 대한 만족감을 표현하며, 이러한 기술 발전이 이 치열한 분야에서 필요한 경쟁 우위를 제공한다고 밝혔습니다.
SOHM, Inc. (OTC PINK:SHMN), une entreprise pharmaceutique et biotechnologique, a déposé une nouvelle demande de brevet provisoire auprès de l'USPTO. La demande, intitulée 'ACIDES NUCLÉIQUES DONNEURS POUR INTÉGRASES GUIDÉES PAR ARN ET SYSTÈME MULTIPLEX D'ARN GUIDE POUR CIBLER', décrit des combinaisons spécifiques d'ARN guide utilisés avec le système ABBIE pour augmenter le ciblage et l'efficacité.
Ce développement survient dix mois après l'annonce par SOHM de leur demande de brevet provisoire pour l'édition génétique 'SMART'. L'entreprise vise à élargir son portefeuille de brevets dans le secteur de l'ingénierie cellulaire, avec l'objectif de devenir un acteur significatif et un leader dans la technologie et les produits d'édition génétique.
Le Dr. David Aguilar, COO de SOHM, a exprimé sa satisfaction quant aux progrès réalisés dans le développement du système ABBIE et son potentiel, déclarant que ces avancées techniques offrent l'avantage concurrentiel nécessaire dans ce domaine hautement concurrentiel.
SOHM, Inc. (OTC PINK:SHMN), ein Pharma- und Biotechnologieunternehmen, hat einen neuen vorläufigen Patentantrag beim USPTO eingereicht. Der Antrag mit dem Titel 'DONOR-NUKLEINSÄUREN FÜR RNA-GEFÜHRTE INTEGRASES UND MULTIPLEX GUIDE RNA-SYSTEM ZUM TARGETING' beschreibt spezifische Kombinationen von Guide-RNAs, die im ABBIE-System verwendet werden, um das Targeting und die Effizienz zu erhöhen.
Diese Entwicklung erfolgt zehn Monate nach der Ankündigung von SOHM über ihren vorläufigen Patentantrag zur 'SMART'-Genbearbeitung. Das Unternehmen hat das Ziel, sein Patentportfolio im Bereich der Zelltechnik zu erweitern, mit dem Ziel, ein bedeutender Akteur und führend in der Genbearbeitungstechnik und- produkten zu werden.
Dr. David Aguilar, COO von SOHM, äußerte seine Zufriedenheit mit den Fortschritten in der Entwicklung des ABBIE-Systems und dessen Potenzial und erklärte, dass diese technischen Fortschritte den Wettbewerbsvorteil bieten, der in diesem stark umkämpften Bereich erforderlich ist.
- Filed new provisional patent application for RNA guided integrases and multiplex guide RNA system
- Expanding patent portfolio in cell engineering and gene editing space
- Continued development of ABBIE system for increased targeting and efficiency
- None.
CHINO HILLS, CA / ACCESSWIRE / October 2, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has filed new provisional patent application with USPTO.
Dr. David Aguilar, COO, SOHM, Inc. announced that the company has filed a new provisional application entitled;
"DONOR NUCLEIC ACIDS FOR RNA GUIDED INTEGRASES AND MULTIPLEX GUIDE RNA SYSTEM FOR TARGETING"
Dr. Aguilar further added that the application describes specific combinations of guide RNAs used with the ABBIE system for increased targeting and efficiency of the ABBIE system. SOHM continues to grow its patent portfolio in the cell engineering space with the intention of becoming a significant player and leader in technology and products for gene editing. This announcement comes just ten months after the announcement of their "SMART" gene editing provisional application leveraging graphene material science with gene editing and cell engineering applications.
We are very happy with our progress in developing our ABBIE system and expanding it's potential. The continued technical advances allow our team to gain the competitive edge needed to be successful in this highly contested space said Dr. David Aguilar COO
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy.
To learn more about SOHM, Inc., visit www.SOHM.com.
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on accesswire.com
FAQ
What new patent application has SOHM Inc (SHMN) filed with the USPTO?
How does the new patent application relate to SOHM's (SHMN) ABBIE system?
What is SOHM Inc's (SHMN) goal in the gene editing and cell engineering space?
When did SOHM Inc (SHMN) announce their 'SMART' gene editing provisional application?
